Lurie D M, Gordon I K, Théon A P, Rodriguez C O, Suter S E, Kent M S
Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.
J Vet Intern Med. 2009 Sep-Oct;23(5):1064-70. doi: 10.1111/j.1939-1676.2009.0353.x. Epub 2009 Jul 14.
Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
Thirty-eight client-owned animals diagnosed with multicentric lymphoma.
Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%.
Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.
序贯半身照射（HBI）联合化疗治疗犬淋巴瘤是可行的，但延长照射间隔可能会影响疗效。对于大多数接受6 Gy剂量水平低剂量率照射（LDRI）方案的犬，2周的照射间隔是可行的。
将LDRI纳入基于环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）的化疗方案对犬淋巴瘤治疗有效。
38只客户拥有的被诊断为多中心淋巴瘤的动物。
回顾性研究评估序贯HBI和化疗治疗犬淋巴瘤的疗效及预后因素。
首次缓解的中位时间为410天（95%置信区间[CI] 241 - 803天）。1年、2年和第3年的首次缓解率分别为54%、42%和31%。总生存的中位时间为684天（95% CI 334 -
1223天）。1年、两年和3年生存率分别为66%、47%和44%。
本研究结果表明，通过2周的照射间隔联合照射期间化疗来强化治疗是犬淋巴瘤的一种有效治疗方法。
